SATSUMA PHARMACEUTICALS INC's ticker is STSA and the CUSIP is 80405P107.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $4,131,105 | -22.4% | 5,914,252 | 0.0% | 0.09% | -13.0% |
| Q4 2022 | $5,322,827 | -85.0% | 5,914,252 | 0.0% | 0.11% | -85.7% |
| Q3 2022 | $35,486,000 | +44.9% | 5,914,252 | 0.0% | 0.76% | +15.9% |
| Q2 2022 | $24,485,000 | +8.9% | 5,914,252 | 0.0% | 0.65% | +33.3% |
| Q1 2022 | $22,474,000 | -15.6% | 5,914,252 | 0.0% | 0.49% | +4.5% |
| Q4 2021 | $26,614,000 | -3.4% | 5,914,252 | 0.0% | 0.47% | +22.8% |
| Q3 2021 | $27,560,000 | -33.9% | 5,914,252 | 0.0% | 0.38% | -42.9% |
| Q2 2021 | $41,695,000 | +19.3% | 5,914,252 | 0.0% | 0.67% | +26.9% |
| Q1 2021 | $34,953,000 | +61.9% | 5,914,252 | +26.3% | 0.53% | +74.5% |
| Q4 2020 | $21,583,000 | +18.5% | 4,681,858 | 0.0% | 0.30% | -9.3% |
| Q3 2020 | $18,212,000 | -86.5% | 4,681,858 | 0.0% | 0.33% | -87.3% |
| Q2 2020 | $134,650,000 | +33.6% | 4,681,858 | 0.0% | 2.62% | -17.6% |
| Q1 2020 | $100,754,000 | +9.4% | 4,681,858 | 0.0% | 3.18% | +13.9% |
| Q4 2019 | $92,139,000 | +31.1% | 4,681,858 | 0.0% | 2.79% | -33.3% |
| Q3 2019 | $70,275,000 | – | 4,681,858 | – | 4.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 870,820 | $13,071,000 | 14.74% |
| RA Capital Management | 4,681,858 | $70,275,000 | 4.19% |
| Cormorant Asset Management, LP | 858,382 | $12,884,000 | 0.78% |
| Monashee Investment Management LLC | 62,500 | $938,000 | 0.43% |
| TPG Group Holdings (SBS) Advisors, Inc. | 3,771,878 | $56,616,000 | 0.42% |
| DC Investments Management, LLC | 35,502 | $533,000 | 0.31% |
| Eventide Asset Management | 425,000 | $6,379,000 | 0.21% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 610,000 | $9,156,000 | 0.02% |
| Weiss Asset Management LP | 14,150 | $212,000 | 0.02% |
| Zimmer Partners, LP | 100,000 | $1,501,000 | 0.02% |